Wall Street analyst estimates for BioVie Inc. (BIVI): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 5 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 5 |
| Avg rating (1-5) | 1.00 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-09 | |||
| 2026-08-12 | $-0.70 | $-0.52 | -34.6% |
| 2026-05-11 | $-0.70 | $-0.73 | +4.1% |
| 2026-02-10 | $-0.77 | $-0.81 | +4.9% |
| 2025-11-10 | $-0.98 | $-0.79 | -24.1% |
| 2025-08-15 | $-1.82 | $-1.82 | +0.0% |
| 2025-05-12 | $-1.50 | $-3.20 | +53.1% |
| 2025-02-11 | $-4.60 | $-16.00 | +71.2% |
Valuation Ratios
| Price / Book | 1.29 |
| EV / EBITDA | -0.31 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $229377 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -$229377 | 0 |
| Research & Development | $466354 | $370853 | $1.0M | $1.2M | $133.2M | $17.3M | $33.3M | $23.1M | $9.3M | $14.0M |
| Selling, General & Admin | $857883 | $1.8M | $1.3M | 0 | 0 | 0 | $11.6M | 0 | $8.6M | $8.5M |
| Operating Expenses | $1.6M | $2.4M | $2.5M | $2.7M | $138.1M | $27.3M | $45.1M | $32.2M | $17.8M | $22.7M |
| Operating Income | -$1.6M | -$2.4M | -$2.5M | -$2.7M | -$138.1M | -$27.3M | -$45.1M | -$32.2M | -$18.1M | -$22.7M |
| EBITDA | -$1.3M | -$2.1M | -$2.3M | -$2.5M | -$129.5M | -$23.7M | -$45.7M | -$29.0M | -$17.0M | -$21.9M |
| Interest Expense | 0 | $40960 | $273 | $4.8M | $559455 | $2.2M | $4.3M | $2.9M | $332720 | $17901 |
| Pre-tax Income | -$1.3M | -$2.4M | -$2.4M | -$16.7M | -$130.2M | -$26.1M | -$50.3M | -$32.1M | -$17.5M | -$22.1M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$1.3M | -$2.4M | -$2.4M | -$16.7M | -$130.2M | -$26.1M | -$50.3M | -$32.1M | -$17.5M | -$22.1M |
| EPS | $-186.10 | $-317.70 | $-98.20 | $-685.20 | $-1482.30 | $-106.00 | $-154.70 | $-73.05 | $-12.12 | $-3.05 |
| EPS (Diluted) | $-186.10 | $-317.70 | $-98.20 | $-685.20 | $-1482.30 | $-106.00 | $-154.70 | $-73.05 | $-12.12 | $-3.05 |
| Shares Outstanding (Diluted) | $7151 | $7661 | $25396 | $49295 | $124031 | $246625 | $324834 | $451853 | $1.5M | $7.2M |
Price
| Price | $1.72 |
| Market Cap | $13M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ARTL · CANF · CERO · ELAB · GLMD · INM · KZIA
Explore sector: Healthcare · Biotechnology
More sections of BIVI: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks